Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both effectiveness and cost. To compare the cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Si Ni, Wan, Xiaomin, Peng, Liu Bao, Li, Ya Min, Li, Jian He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847087/
https://www.ncbi.nlm.nih.gov/pubmed/36653848
http://dx.doi.org/10.1186/s12913-023-09058-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847087/
https://www.ncbi.nlm.nih.gov/pubmed/36653848
http://dx.doi.org/10.1186/s12913-023-09058-7

Ejemplares similares